Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Large B-Cell, Diffuse

Explore clinical trials studying Lymphoma, Large B-Cell, Diffuse. Study availability and eligibility vary by location and protocol.

1,249 public trials 217 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Large B-Cell, Diffuse trial results

Completed

Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

NCT03010982

Conditions
Advanced Solid Tumors, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, +17 more
Locations
  • The Clatterbridge Cancer Centre NHS Foundation Trust Bebington, Wirral, United Kingdom
  • Royal Liverpool and Broadgreen University Hospital Trust Liverpool, United Kingdom
View Trial Details
Completed

Study of Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

NCT02926833

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • City of Hope Duarte, California, United States
  • Stanford Cancer Center Palo Alto, California, United States
  • H Lee Moffitt Cancer Center Tampa, Florida, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

Immune Responses to COVID-19 Vaccination in Lymphoma Patients

NCT04858568

Conditions
Burkitt Lymphoma, Chronic Disease, Chronic Lymphocytic Leukemia, +42 more
Locations
  • Bedfordshire Hospitals NHS Foundation Trust Bedford, Bedfordshire, United Kingdom
  • Portsmouth Hospitals University NHS Trust Portsmouth, Hampshire, United Kingdom
  • University Hospital Southampton NHS Foundation Trust Southampton, Hampshire, United Kingdom
  • Wye Valley NHS Trust Hereford, Herefordshire, United Kingdom
View Trial Details
Completed

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

NCT03543813

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +29 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • California Cancer Associates for Research and Excellence Encinitas, California, United States
  • University of Southern California Los Angeles, California, United States
  • Yale Cancer Center New Haven, Connecticut, United States
View all 25 locations
View Trial Details
Completed

Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)

NCT02658968

Conditions
AIDS-Related Complex, Blood-Borne Infections, Communicable Diseases, +29 more
Locations
  • University of California, San Diego (UCSD) - Moores Cancer Center San Diego, California, United States
  • University of California, San Francisco (UCSF) - Innovation, Technology & Alliances San Francisco, California, United States
  • Sylvester Comprehensive Cancer Centre Miami, Florida, United States
  • Klinikum rechts der Isar der TU München Munich, Germany
View Trial Details
Completed

A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)

NCT03833180

Conditions
Acute Lymphoid Leukemia, Acute Myeloid Leukemia, Blood Protein Disorders, +49 more
Locations
  • City of Hope ( Site 0010) Duarte, California, United States
  • University of California - San Diego ( Site 0003) La Jolla, California, United States
  • UCLA Hematology & Oncology ( Site 0007) Los Angeles, California, United States
  • University of Nebraska Medical Center ( Site 0006) Omaha, Nebraska, United States
View all 14 locations
View Trial Details

Related conditions